Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Intravenous Triapine® (IND #68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies.

NCT00335998 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00335998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00335998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Intravenous Triapine® (IND #68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies.
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2006
Completion date
Not reported
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent cervical cancer, recurrent ovarian epithelial cancer, recurrent vaginal cancer, recurrent vulvar cancer, stage iii vaginal cancer, stage iiia cervical cancer, stage iiia ovarian epithelial cancer, stage iiia vulvar cancer, stage iiib cervical cancer, stage iiib ovarian epithelial cancer, stage iiib vulvar cancer, stage iiic ovarian epithelial cancer, stage iiic vulvar cancer, stage iv ovarian epithelial cancer, stage iva cervical cancer, stage iva vaginal cancer, stage ivb cervical cancer, stage ivb vaginal cancer